[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_95":96},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","pfkclpnaomrszxjjfocnsawra","revision",2,"title","Polyrizon Ltd. 提交美国专利申请，拓展鼻内给药平台的知识产权保护","originalTitle","6-K - Polyrizon Ltd. (0001893645) (Filer)","summary","Polyrizon Ltd. 在 10 月 5 日发布新闻稿，称已提交一项美国专利申请，旨在拓展其鼻内给药平台的知识产权保护。公司通过 Form 6-K 向 SEC 提交了该新闻稿。","reason","source",{"_11":85,"_86":87,"_88":89,"_90":57,"_91":92,"_93":94},"links",{"_82":83,"_63":84},"publishedAt","2026-10-05T20:00:22.000Z","discoveredAt","2026-10-05T23:41:49.348Z","timelineAt","category","ai-products","tags",[81],"stockSymbols",[80],"score",16,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fr3vA3Pt0_fE",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","f6ff5037-63bc-4faa-a36a-858f9f0253b8","Polyrizon提交美国专利申请",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October 2026

Commission file number: 001-42375

Polyrizon Ltd.

(Translation of registrant’s name into English)

8 Ha-Pnina Street

Raanana, 4321545, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual\nreports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form\n40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s\npress release issued on October 5, 2026, titled “Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal\nDrug-Delivery Platform.”

EXHIBIT INDEX

\n \n \n \n \n \n \n \n \n

Exhibit No.
99.1		Press release titled: “Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform”

SIGNATURES

Pursuant to the requirements of the Securities Exchange\nAct of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	Polyrizon Ltd.

Date: October 5, 2026	By:	/s/ Tomer Izraeli
	Name:	Tomer Izraeli
	Title:	Chief Executive Officer

","zhKind","complete","PLRZ","公司与财报","aihot","/items/pfkclpnaomrszxjjfocnsawra","https://www.sec.gov/Archives/edgar/data/1893645/000121390026106814/0001213900-26-106814-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791504000&sig=503fb7d170765eee","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791504000&sig=bd7a734cec863d9b 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791504000&sig=e5a5cfd96e0c1fd2 96w","changelogVersion","2026-10-01T08:00"]